drug · small molecule
DYANAVEL XR 20
Marketedupdated 3mo agoby $TRAW Traws Pharma, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugDYANAVEL XR252 co-mentions · 84 sources
- drugamfetamine ER-ODT206 co-mentions · 84 sources
- tagApproval186 co-mentions · 70 sources
- drugdextroamphetamine98 co-mentions · 14 sources
- drugdextroamphetamine ER98 co-mentions · 14 sources
- tagSmall Molecule93 co-mentions · 70 sources
- drugamfetamine72 co-mentions · 37 sources
- drugAMPHETAMINE SULFATE72 co-mentions · 37 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for attention deficit hyperactivity disorder and 3 investigational indications.
targets
Sodium-dependent dopamine transporterSodium-dependent noradrenaline transporter
all catalysts(6)
approval · 6
Nov 4, 2021
approval
$TRAW
DYANAVEL XR 20 (AMPHETAMINE) — FDA approval
DYANAVEL XR 20
→
Feb 25, 2022
approval
$TRAW
DYANAVEL XR 20 (AMPHETAMINE) — FDA approval
DYANAVEL XR 20
→
Jun 1, 2022
approval
$TRAW
DYANAVEL XR 20 (AMPHETAMINE) — FDA approval
DYANAVEL XR 20
→
Oct 14, 2022
approval
$TRAW
DYANAVEL XR 20 (AMPHETAMINE) — FDA approval
DYANAVEL XR 20
→
Oct 13, 2023
approval
$TRAW
DYANAVEL XR 20 (AMPHETAMINE) — FDA approval
DYANAVEL XR 20
→
Sep 23, 2025
approval
$TRAW
DYANAVEL XR 20 (AMPHETAMINE) — FDA approval
DYANAVEL XR 20
→
Trials studying DYANAVEL XR 20
- phase4EEG Biomarkers for ADHD Stimulant Treatment
- phase3MDMA-assisted Massed Prolonged Exposure for PTSD
- phase1A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users
- phase2A Phase 2A Trial of DT402 for Autism Spectrum Disorder
- phase2A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
- phase3MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD
- —A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
- phase1A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 15, 2027
216 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Feb 11, 2040method-of-use (U-3538)US 12458592
- Sep 24, 2038formulationUS 11590081
- Mar 15, 2027formulationUS 8337890216d
- Mar 15, 2027formulationUS 8747902216d
- Mar 15, 2027formulationUS 9675704216d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that